$TEVA - 52% up from the first Graph I published Next challenge is visiting MA200 - touch and go.
Good luck
T1EV34 trade ideas
Ze reversalFull send, no stop loss
Performed well in '08 recession
Juicy yield, in a period where investors are desperate for it
3.2 forward p/e
Fat bull div
BUY TEVA!* It looks like the company starts to recover.
* The company is traded undervalued.
* Looks like a good point to buy.
* Trend has changed to bullish
$TEVA - I wish for upside trend line break.
case of breaking, 7.15-7.1 is the first resistance.
Good-luck and Shabbat shalom :)
$TEVA bullish reversal tradePossible entry level $9.80 = Target price $11.00 = Stop loss $9.50.
Huge momentum swing in Teva, earnings may have been a disappointment but guidance and outlook turned investors bullish and may be a sign of a bottom in for the stock.
The stock is now above its average analysts price target of $8.88 so they will forced to regrade the stock, hopefully bullishly.
Alert set for break above 70 on the RSI
$TEVA Turnaround may have begun in Teva Pharmaceutical.Teva Pharmaceutical Industries (NYSE:TEVA) Q3 results:
Revenues: $4,264M (-5.9%).
Key product sales: Copaxone: $397M (-33.9%); Generics: $2,224B (-1.8%).
Net loss: ($314M) (-15.0%); non-GAAP net income: $637M (-8.2%); loss/share: ($0.29) (-7.4%); non-GAAP EPS: $0.58 (-14.7%).
Cash flow ops: $325M (-22.8%).
2019 guidance: Revenues: $17.2B - 17.4B from $17.0B - 17.4B; operating income: $4.0B - 4.2B from $3.8B - 4.2B; EBITDA: $4.5B - 4.8B from $4.4B - 4.8B; EPS: $2.30 - 2.50 from $2.20 - 2.50; free cash flow: $1.7B - 2.0B from $1.6B - 2.0B.
Eli Kalif appointed EVP and Chief Financial Officer effective December 22. He joins the firm from Flex Ltd where he was SVP Finance Global Operations, Components & Services.
Shares up 4% premarket on increased volume.
Previously: Teva Pharmaceutical EPS misses by $0.01, beats on revenue (Nov. 7)
Source Seeking Alpha
Short interest relatively high at 7%
Company profile
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines. The Generic Medicines segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment engages in the provision of core therapeutic areas of central nervous system medicines. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
Ascending Triangle Breakout from Double Bottom for up trend ideaAfter years of going from top-left to bottom-right, there was a Double Bottom bounce with an Ascending Triangle currently sitting at the top of bounce. NASDAQ pre-market volume is quite nice, and the weekly volume has been consistent with price movement direction. The weekly EMA and SMA are moving from vertical to horizontal, the last three weekly candles are currently green, and the angle from the lowest weekly opening to the current price is pointing (from left to right) in an up direction. Good luck to all.
Stock TEVA LONG "W" formationBreak 8.3 and close above (on daily)
Then wait for the pull back ~8.30
Long ratio +1.5
Long TEVA Long TEVA
I'm long 6,000 shares at $7.41 average; started accumulating July 16, 2019.
Bullish divergence on monthly and weekly time scales.
Descending triangle breakout on the daily with huge volume.
First target = $14.15 (gap that has yet to close)
Opioid lawsuits settled today and TEVA scored a huge win in the settlement.
TEVA - LONG IDEA.Teva creates a nice oppurtunity for a long trade. Two days ago was moving almost 20 percent upward when it reached and published a fine settelment.
I'm going to monitor that deal with a very close stop-loss because it is still being manipulated, what makes it a bit risky.
Long TEVALong TEVA
6,000 shares at $7.41 average.
Bullish divergence on month and weekly time scales.
Settled opioid suits today, earnings 11/7/19.
First target $13.95
SWMA - ShortI speculate that it will go throug the MA200 on day-graph. Would buy if it goes down to the support line and then hold for long time
Teva price consolidatingTEVA’s innovation outlook is neutral based on a current score of 56 out of 99, outperforming sector average. Insiders sentiment is positive. TEVA is an Average Performer in terms of sustainability. Over the past 4 quarters TEVA beat earnings estimates 3 times.
For more analysis and articles visit our website.
TEVA - Price and volume breakoutTEVA share prices reversed to the upside in the previous session and continued its push to the upside in today's session, breaking through the 8.00 target. The next target is estimated at 8.90
Not much stopping Teva from going up TEVA will be going long from here for some Time. Maybe will see it in the $11 or so range in a couple months. Just ideas. I would like to hear yours. I do have positions at $6.40 and $7.12.
STILL BUYING! ADDED 750,000 SHARESWe feel, in our opinion, TEVA is dirt cheap at these levels.
The company is in a turn-around phase and things are looking very good especially after picking through recent earnings.
We've done amazing with out picks as everyone can see. We are currently only holding 6 stocks.
TEVA is a long term play. Sit and hold.
Thank you for following us.
Best of luck to all!
DISCLAIMER
This website and our posts are for general information only. No information, forward looking statements, or estimations presented herein represent any final determination on investment performance. While the information presented in this website and our posts has been researched and is thought to be reasonable and accurate, any investment is speculative in nature. StockKid, and/or our agents cannot and do not guarantee any rate of return or investment timeline based on the information presented herein.
By reading and reviewing the information contained in this website and our posts, the user acknowledges and agrees that StockKid, and/or our agents do not assume and hereby disclaim any liability to any party for any loss or damage caused by the use of the information contained herein, or errors or omissions in the information contained in this website or our posts, to make any investment decision, whether such errors or omissions result from negligence, accident or any other cause.
Investors are required to conduct their own investigations, analysis, due diligence, draw their own conclusions, and make their own decisions. Any areas concerning taxes or specific legal or technical questions should be referred to lawyers, accountants, consultants, brokers, or other professionals licensed, qualified or authorized to render such advice.
In no event shall StockKid, and/or our agents be liable to any party for any direct, indirect, special, incidental, or consequential damages of any kind whatsoever arising out of the use of this website, our posts or any information contained herein. StockKid, and/or our agents specifically disclaim any guarantees, including, but not limited to, stated or implied potential profits, rates of return, or investment timelines discussed or referred to herein.
